Comparative Pharmacology
Head-to-head clinical analysis: MICROZIDE versus ORETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROZIDE versus ORETIC.
MICROZIDE vs ORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes, and a decrease in blood volume and peripheral vascular resistance.
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
12.5-25 mg orally once daily for hypertension; 25-100 mg orally once daily for edema.
25-100 mg orally once or twice daily; maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment; up to 30 hours in severe insufficiency).
Terminal elimination half-life: 6-15 hours (average 10 hours); prolonged in renal impairment and heart failure; clinical context: duration of diuretic effect correlates with half-life, requiring once or twice daily dosing.
Primarily renal (approximately 70% unchanged drug; remainder as metabolites and conjugates); minimal biliary/fecal (<10%).
Renal: approximately 95% (primarily as unchanged drug via tubular secretion), Biliary/fecal: <5%
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic